An immunotherapeutic composition comprising: a) a yeast vehicle, wherein the yeast vehicle is a whole, killed, or inactivated yeast; and b) a fusion protein comprising HIV antigens, wherein the HIV antigens comprise or consist of: (i) the amino acid sequence of SEQ ID NO: 5; (ii) the amino acid sequence of SEQ ID NO: 5, wherein; (a) the epitope of SEQ ID NO: 76 is substituted for one of the APL epitopes consisting of SEQ ID NOs: 14-19 or SEQ ID NOs: 44-49; and/or (b) the epitope of SEQ ID NO: 77 is substituted for one of the APL epitopes consisting of SEQ ID NOs: 20-25 or SEQ ID NOs: 50-55; and/or (c) the epitope of SEQ ID NO: 78 is substituted for one of the APL epitopes consisting of SEQ ID NOs: 26-31 or SEQ ID NOs: 56-61; and/or (d) the epitope of SEQ ID NO: 79 is substituted for one of the APL epitopes consisting of SEQ ID NOs: 32-37 or SEQ ID NOs: 62-67; and/or (e) the epitope of SEQ ID NO: 80 is substituted for one of the APL epitopes consisting of SEQ ID NOs: 38-43 or SEQ ID NOs: 68-73; or (iii) an amino acid sequence that is at least 95% identical to amino acid sequence of SEQ ID NO: 5 and that elicits an HIV antigen-specific cell-mediated immune response, wherein the fusion protein is expressed by the yeast vehicle. a) a yeast vehicle, wherein the yeast vehicle is a whole, killed, or inactivated yeast; and b) a fusion protein comprising HIV antigens, wherein the HIV antigens comprise or consist of: (i) the amino acid sequence of SEQ ID NO: 5; (ii) the amino acid sequence of SEQ ID NO: 5, wherein; (a) the epitope of SEQ ID NO: 76 is substituted for one of the APL epitopes consisting of SEQ ID NOs: 14-19 or SEQ ID NOs: 44-49; and/or (b) the epitope of SEQ ID NO: 77 is substituted for one of the APL epitopes consisting of SEQ ID NOs: 20-25 or SEQ ID NOs: 50-55; and/or (c) the epitope of SEQ ID NO: 78 is substituted for one of the APL epitopes consisting of SEQ ID NOs: 26-31 or SEQ ID NOs: 56-61; and/or (d) the epitope of SEQ ID NO: 79 is substituted for one of the APL epitopes consisting of SEQ ID NOs: 32-37 or SEQ ID NOs: 62-67; and/or (e) the epitope of SEQ ID NO: 80 is substituted for one of the APL epitopes consisting of SEQ ID NOs: 38-43 or SEQ ID NOs: 68-73; or (iii) an amino acid sequence that is at least 95% identical to amino acid sequence of SEQ ID NO: 5 and that elicits an HIV antigen-specific cell-mediated immune response, wherein the fusion protein is expressed by the yeast vehicle. (i) the amino acid sequence of SEQ ID NO: 5; (ii) the amino acid sequence of SEQ ID NO: 5, wherein; (a) the epitope of SEQ ID NO: 76 is substituted for one of the APL epitopes consisting of SEQ ID NOs: 14-19 or SEQ ID NOs: 44-49; and/or (b) the epitope of SEQ ID NO: 77 is substituted for one of the APL epitopes consisting of SEQ ID NOs: 20-25 or SEQ ID NOs: 50-55; and/or (c) the epitope of SEQ ID NO: 78 is substituted for one of the APL epitopes consisting of SEQ ID NOs: 26-31 or SEQ ID NOs: 56-61; and/or (d) the epitope of SEQ ID NO: 79 is substituted for one of the APL epitopes consisting of SEQ ID NOs: 32-37 or SEQ ID NOs: 62-67; and/or (e) the epitope of SEQ ID NO: 80 is substituted for one of the APL epitopes consisting of SEQ ID NOs: 38-43 or SEQ ID NOs: 68-73; or (a) the epitope of SEQ ID NO: 76 is substituted for one of the APL epitopes consisting of SEQ ID NOs: 14-19 or SEQ ID NOs: 44-49; and/or (b) the epitope of SEQ ID NO: 77 is substituted for one of the APL epitopes consisting of SEQ ID NOs: 20-25 or SEQ ID NOs: 50-55; and/or (c) the epitope of SEQ ID NO: 78 is substituted for one of the APL epitopes consisting of SEQ ID NOs: 26-31 or SEQ ID NOs: 56-61; and/or (d) the epitope of SEQ ID NO: 79 is substituted for one of the APL epitopes consisting of SEQ ID NOs: 32-37 or SEQ ID NOs: 62-67; and/or (e) the epitope of SEQ ID NO: 80 is substituted for one of the APL epitopes consisting of SEQ ID NOs: 38-43 or SEQ ID NOs: 68-73; or (iii) an amino acid sequence that is at least 95% identical to amino acid sequence of SEQ ID NO: 5 and that elicits an HIV antigen-specific cell-mediated immune response,